AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03036254 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham intervention
Description: Sham was selected as the control condition rather than usual care to equate intervention groups with respect to other variables that could influence cognition and functional status, such as a new challenge (completing an activity program), peer socialization, and attention from staff.
Study NCT00718913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel will be given at 60 mg/m2, as a 60-minute infusion every 3 weeks for 2 cycles before chemo-radiation. Four to five weeks after completion of chemo-radiation therapy, all patients will receive two more cycles of Docetaxel 60 mg/m2.
Study NCT00718913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin will be given at 60 mg/m2, as 2-hour infusion every 3 weeks for 2 cycles before chemo-radiation. Four to five weeks after completion of chemo-radiation therapy, all patients will receive two more cycles of Cisplatin at 60 mg/m2.
Study NCT00718913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine will be given orally at 1800 mg/m2 days 1 through 14 divided in two daily doses before chemo-radiation. Four to five weeks after completion of chemo-radiation therapy, all patients will receive two more cycles of Capecitabine at 1800 mg/m2 days 1 through 14 (divided in two daily doses).
Study NCT00718913 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: At the end of the second cycle of chemotherapy and one week of rest (day 27), a total of 45 Gy (1.8 Gy fx/d) of radiotherapy will be given.
Study NCT00718913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine will be administered orally during radiotherapy for radiosensitization(1650 mg/m2 per day divided in two daily doses, 5 days/week, on Monday through Friday).
Study NCT04354116 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rapid maxillary expansion
Description: Palatal expanders of the HYRAX type, with bands on the first permanent molars will be used for patients in both groups. In the experimental group, the expander will be anchored mesially and bilaterally in mini-implants, in a technique known as rapid maxillary expansion assisted by mini-implants (MARPE). The control active group will be with conventional HYRAX expanders. The maxillary expansion protocol will be once a day for 2 weeks.
Study NCT04354116 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rapid maxillary expansion
Description: Palatal expanders of the HYRAX type, with bands on the first permanent molars will be used for patients in both groups. In the experimental group, the expander will be anchored mesially and bilaterally in mini-implants, in a technique known as rapid maxillary expansion assisted by mini-implants (MARPE). The control active group will be with conventional HYRAX expanders. The maxillary expansion protocol will be once a day for 2 weeks.
Study NCT04354116 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Maxillary Protraction
Description: Protraction hooks will be projected around the upper canine area. In the experimental group (MARPE), the appliance will be anchored mesially and bilaterally in mini-implants. The control active group will be anchored with conventional HYRAX expanders. Both groups will be treated with maxillary protraction with a Petit-type face mask at night (12 hours a day).
Study NCT04354116 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Maxillary Protraction
Description: Protraction hooks will be projected around the upper canine area. In the experimental group (MARPE), the appliance will be anchored mesially and bilaterally in mini-implants. The control active group will be anchored with conventional HYRAX expanders. Both groups will be treated with maxillary protraction with a Petit-type face mask at night (12 hours a day).
Study NCT03760913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OLP-1002 (Test): Part A, Single Ascending Dose
Description: Subcutaneous Injection: 30 ng, 120 ng, 400 ng, 1.2 µg, 3 µg, 6 µg, 12 µg, 20 µg, 40 μg, 80 μg, 160 μg
Study NCT03760913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OLP-1002 (Test): Part B, Multiple Ascending Dose
Description: Subcutaneous Injection: 5 x 2 μg, 5 x 5 μg, 5 x 10 μg, 5 x 20 μg, 5 x 40 μg, 5 x 80 μg
Study NCT03760913 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo: Placebo Part A, Single Ascending Dose
Description: Subcutaneous Injection: Placebo
Study NCT03760913 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo: Placebo Part B, Multiple Ascending Dose
Description: Subcutaneous Injection: Placebo x 5
Study NCT02419703 — intervention group
Intervention type: DEVICE
Intervention: STAR™ Tumor Ablation System
Description: Targeted Radiofrequency ablation of painful metastatic tumor in the vertebral body.
Study NCT02154295 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Infraredx Test Catheter
Study NCT02598947 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual therapy
Description: Exercise, behaviour change interventions and manual therapy
Study NCT02598947 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Manual therapy
Description: Exercise, behaviour change interventions and manual therapy
Study NCT04335786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan (Diovan)
Description: At the time of randomization each participant will start with study treatment and continue up to 14 days, or up to reaching the primary endpoint, or up to hospital discharge, or up to any of the pre-defined stopping criteria.~Study drug dosages will be titrated to blood pressure with a maximum of 160mg b.i.d.
Study NCT00216086 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EUS
Description: biopsy per EUS
Study NCT00216086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant Chemotherapy
Description: * Irinotecan 200 mg/m2 IV, day 1~* Capecitabine 1000 mg/m2 po bid day 1-14; repeat every three weeks for two cycles
Study NCT00216086 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Preoperative Radiation
Description: Pelvic XRT 45 Gy/1.8 GY/fx/qd+5/4 Gy/1.8 Gy/fx/qd for T3+9 Gy/1.8/Gy/fx/qd for T4
Study NCT00216086 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Surgery within 8 weeks following chemoradiotherapy
Study NCT00216086 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adjuvant Chemotherapy
Description: Adjuvant chemotherapy at investigator's discretion
Study NCT02036112 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional ELAPE
Description: device
Study NCT02036112 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Individual ELAPE
Description: device
Study NCT04335786 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: At the time of randomization each participant will start with study treatment and continue up to 14 days, or up to reaching the primary endpoint, or up to hospital discharge, or up to any of the pre-defined stopping criteria.
Study NCT03450252 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active pacing
Description: Ventricular pacing via the invasive haemodynamic study-defined optimal pacing site in order to relieve pressure gradient across the mid-cavity obstruction in mid-cavity obstructive variant hypertrophic cardiomyopathy.
Study NCT03450252 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Back-up pacing
Description: Back-up pacing. The pacemaker is set-up to sense and pace only in the right atrium (AAI) without any pacing capacity in the ventricle.
Study NCT04147923 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Floradapt Mature Immune Defense + Multivitamin
Description: The product consists of two L. plantarum strains, KABP XXXX and KABP XXXX with a combined strength of >1 x 10\^9 CFU. Participants will also consume a multivitamin.
Study NCT04147923 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + Multivitamin
Description: No active ingredients + a multivitamin supplement
Study NCT01939574 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chemoradiation Therapy
Description: * Radiation therapy:For both intensity-modulated radiation therapy (IMRT) and three-dimensional conformal radiation therapy (3D-CRT) plans, one treatment of 2 Gy will be given daily 5 days per week for a total of 60 Gy over 6 weeks.~* Temozolomide will be administered continuously from day 1 of radiotherapy to the last day of radiation at a daily oral dose of 75 mg/m2 for a maximum of 49 days.~* Bevacizumab will be administered intravenously on days 1 and 15 of each 28-day cycle,at the beginning of the 4th week of radiation. The dose will be 10 mg/kg of actual body weight.
Study NCT01939574 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adjuvant Therapy
Description: * Temozolomide will be administered orally once per day for 5 consecutive days (days 1-5) of a 28-day cycle. The starting dose for the first cycle will be 150 mg/m2/day, with a single dose escalation to 200 mg/m2/day in subsequent cycles if no treatment-related adverse events> grade 2 are noted.~* Bevacizumab will be administered intravenously on days 1 and 15 of each 28-day cycle. The dose will be 10 mg/kg of actual body weight.
Study NCT04292652 — intervention group
Intervention type: PROCEDURE
Intervention: AAA surgery
Description: EVAR is a mini invasive procedure to exclude aortic aneurysms with the intention to prevent rupture. Open repair is the traditional open surgical procedure for the same condition.
Study NCT01593943 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHARM
Description: CHARM will be conducted via three 30-minute counseling sessions delivered in the rural setting, with the first session required and the 2nd and 3rd sessions optional. The first two CHARM sessions will be for men only to build family planning (FP) and gender equity (GE) awareness and investment, and the third session will be for the couple with an emphasis on FP services, shared decision-making and marital communication. The three sessions can occur anytime within a 3 month timeframe but with a minimum of 1 week between sessions. All sessions and FP services (pill, condom, EC) will be provided at no cost to patients.
Study NCT03107247 — intervention group
Intervention type: DRUG
Intervention: Imaging Time
Description: Participants will be asked to be imaged at an additional time point.
Study NCT06336395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Oral
Study NCT06336395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Oral
Study NCT04597788 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional low calorie diet program
Description: Low calorie diet consists of 1200 to 1500 calories will be educated and lifestyle modification will be encouraged for participants in control group. Educational materials as well as recipes for low calorie diet will be provided in individual sessions. Mobile counseling will also be offered for sticking to the diet program.
Study NCT03793738 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anterior component separation
Study NCT03793738 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Posterior component separation
Study NCT06336395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Intravenous
Study NCT06336395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Oral/ intrathecal/intravenous/subcutaneous
Study NCT06336395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-Asparaginase
Description: Intramuscular
Study NCT06336395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated asparaginase
Description: Intravenous
Study NCT06336395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erwinase
Description: Optional for those allergic to E.coli/PEG L-asparaginase (intravenous)
Study NCT06336395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Indicated only for ALL with BCR::ABL1 /BCR::ABL1-like/ tyrosine kinase fusion positive (oral)
Study NCT06336395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: Indicated only for ALL with BCR::ABL1 /BCR::ABL1-like/ tyrosine kinase fusion positive (oral)
Study NCT06336395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Intravenous
Study NCT06336395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Subcutaneous/ Intravenous
Study NCT06336395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mercaptopurine
Description: Oral
Study NCT06336395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thioguanine
Description: Oral
Study NCT06336395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Intravenous
Study NCT06336395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Intravenous
Study NCT06336395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Intravenous
Study NCT00000116 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin A
Description: 15000 IU/d as retinyl palmitate
Study NCT00000116 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin A
Description: 15000 IU/d as retinyl palmitate
Study NCT00000116 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid
Description: 1200 mg/d
Study NCT00000116 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control fatty acid
Study NCT00938249 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Monascus Garlic Fermented Extract
Study NCT00938249 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04278755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drospirenone-Ethinyl Estradiol Oral Tablet
Description: 3 Mg-0.03 Mg continuous daily Drospirenone-Ethinyl Estradiol.
Study NCT03253367 — intervention group
Intervention type: OTHER
Intervention: Blood is obtained, mostly during routine venipuncture
Study NCT01616030 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Knee-extension strength training of the fractured limb
Description: Daily knee-extension strength training with 3 x 10 repetitions using an intensity of 10 Repetition Maximum (RM) for the hip fractured limb started as soon as possible after surgery.
Study NCT01932723 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lumbar stabilization exercises
Description: The functional lumbar stabilization exercises was performed daily, 10 repetitions each, three times a day for three months consecutively.
Study NCT02903030 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Maltose (placebo)
Description: Maltose with a trace amount of silicon dioxide
Study NCT02903030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Visbiome Extra Strength
Description: It is a mix of 8 strains of beneficial bacteria that should improve gut flora, improving GI function and hopefully anxiety
Study NCT00124761 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Surgery + WBRT
Description: Surgery - complete excision of Solitary Brain Metastasis with 30 Gy in 10 fractions over 2 2 1/2 weeks
Study NCT00124761 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiosurgery + WBRT
Description: Radiosurgery - Marginal dose based on maximum tumour diameter
Study NCT01318486 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Heparin free dialysis technique
Description: Saline flushes or predilution
Study NCT01318486 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Evodial
Description: Evodial dialyer
Study NCT02424110 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: argon beam coagulator ablation
Description: The investigators plan to use argon beam coagulator ablation plus bipolar radiofrequency ablation in the argon beam coagulator ablation group.
Study NCT02424110 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bipolar radiofrequency ablation
Description: The investigators only use bipolar radiofrequency ablation in the left and right atrial radiofrequency ablation.
Study NCT02424110 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: argon beam coagulator （American，Valleylab）
Description: Argon beam coagulator（American，Valleylab）will be used in the argon beam coagulator ablation group
Study NCT02424110 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: bipolar radiofrequency (AtricuteTM)
Description: The investigators plan to use bipolar radiofrequency(AtricuteTM) in the bipolar radiofrequency group
Study NCT01708148 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotics
Description: lyophilised L. rhamnosus, L. jensenii, L. crispatus, L. gasseri and sodium alginate
Study NCT04267458 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: evaluation of sofuspovir containing DAA regien expected insult on kidney
Description: to use different kidney biomarkers to evaluate acute kidney damage after using sofuspovir containing DAA regimen in treatment of HCV
Study NCT04435132 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PCL under fluoroscopy with the aid of the robotic device
Description: During the surgery, the robot was positioned over the estimated insertion point. It was aligned to be parallel to the fluoroscope imaging plane as much as possible. The needle is to be placed through the holder, and slightly penetrate the surface of the skin. An x-ray image is then taken to ensure that the whole device can be seen on the screen. Image calibration is then performed through the software GUI. After which, the clinician is also to perform needle tip selection. After which, needle alignment will then be performed. Once needle alignment is complete, the clinician will then advance the trocar needle into the patient's body, using the fluoroscopy to judge the penetration depth. Once the target has been reached, the needle style is to be extracted. The indication of leakage of fluid through the outer needle confirms the success of the procedure.
Study NCT03174834 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Bladder Stimulation technique
Description: The bladder stimulation technique is performed following genital cleaning with a 2% castile soap towelette, which is part of the sterile clean catch urine collection cup kit. For the technique, infants will be held under their armpits by a parent over the bed, with legs dangling in males and hips flexed in females. The nurse or technician will then alternate between bladder stimulation maneuvers: gentle tapping in the suprapubic area at a frequency of 100 taps per minute for 30 seconds followed by lumbar paravertebral massage maneuvers for 30 seconds. These two stimulation maneuvers will be repeated until micturition begins, or for a maximum of 300 seconds.
Study NCT00627120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VGX-1027
Description: Subject will be given a single dose of VGX-1027 ranging from 1-800mg and monitored for safety and pharmacokinetics for 8 days.
Study NCT03585257 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 25% IV albumin
Description: Intravenous 25% albumin infusion 1.0 g/kg body weight (maximum 100gm) once a week for five weeks for a maximum of 5 infusions. These infusions will be administered over sixty minutes per clinical treatment protocols for this population. Patients and investigators will be blinded as to the characteristic of the infusion. Pre-infusion serum albumin will be checked and if >4.0gm/dl, then normal saline will be given instead as mentioned in the blinding section above. Samples will be collected before and one hour after the infusion for all patients.~The total grams of albumin infused over the 4 weeks during and outside the study will be collected and compared between groups.
Study NCT03585257 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline infusion 1.0g/kg body weight once a week for five weeks for a maximum of 5 infusions. These infusions will be administered over sixty minutes per clinical treatment protocols for this population. Patients and investigators will be blinded as to the characteristic of the infusion. Pre-infusion serum albumin will be checked and if >4.0gm/dl, then normal saline will be given instead as mentioned in the blinding section above. Samples will be collected before and one hour after the infusion for all patients.~The total grams of albumin infused over the 4 weeks during and outside the study will be collected and compared between groups.
Study NCT01914198 — intervention group
Intervention type: OTHER
Intervention: Sleep apnea symptom survey
Description: Parents or caregivers will complete a questionnaire regarding possible sleep apnea symptoms.
Study NCT04212650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: Losartan will be administered to improve the quality of hip cartilage repair following arthroscopic microfracture. Losartan is a known anti-fibrotic agent via blocking of TGF-B1.
Study NCT04212650 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Appearance-matched microcrystalline cellulose placebo
Study NCT01118221 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: pulmonary rehabilitation
Description: structured exercise program